1. Home
  2. INFQ vs ZLAB Comparison

INFQ vs ZLAB Comparison

Compare INFQ & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INFQ

Infleqtion Inc. Common Stock

N/A

Current Price

$12.50

Market Cap

2.7B

Sector

Technology

ML Signal

N/A

Logo Zai Lab Limited

ZLAB

Zai Lab Limited

HOLD

Current Price

$20.74

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INFQ
ZLAB
Founded
2007
2013
Country
United States
China
Employees
205
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.4B
IPO Year
2026
2017

Fundamental Metrics

Financial Performance
Metric
INFQ
ZLAB
Price
$12.50
$20.74
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$20.00
$49.60
AVG Volume (30 Days)
10.3M
623.7K
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.46
EPS
N/A
N/A
Revenue
N/A
$460,156,000.00
Revenue This Year
$25.46
$9.75
Revenue Next Year
$25.00
$26.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
15.33
52 Week Low
$8.52
$15.96
52 Week High
$21.28
$44.34

Technical Indicators

Market Signals
Indicator
INFQ
ZLAB
Relative Strength Index (RSI) 47.86 49.20
Support Level $10.98 $16.88
Resistance Level $13.70 $25.28
Average True Range (ATR) 1.06 1.03
MACD -0.04 -0.18
Stochastic Oscillator 36.10 56.48

Price Performance

Historical Comparison
INFQ
ZLAB

About INFQ Infleqtion Inc. Common Stock

Infleqtion Inc developing and commercializing quantum technology products as part of a full-stack platform, which currently includes offerings such as quantum sensing, quantum computing, and software. Its quantum-enabled solutions are focused on addressing the world's pressing challenges, with technologies actively deployed across some sectors today, including defense and security, artificial intelligence (AI), energy optimization, space and frontier, materials discovery, and cybersecurity.

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

Share on Social Networks: